Avalyn Pharma Inc. (AVLN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $67.00K; Additional Paid in Capital, Common StockUSD $719.54M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-95.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $24.00K; Additional Paid in Capital, Common StockUSD $27.95M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $12.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $24.00K; Additional Paid in Capital, Common StockUSD $26.55M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $134.00K.
- 2025-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m).
Avalyn Pharma Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $67.00K | $719.54M | $-95.00K | $-321.17M | $398.35M | (m) | 3 month · $4.23M | 3 month · $2.79M | 6 month · $184.00K |
| 2026-03-31 | (m) | $24.00K | $27.95M | $12.00K | $-292.23M | $-264.25M | $372.22M | (m) | 3 month · $1.19M | 3 month · $184.00K |
| 2025-12-31 | $0.00 | $24.00K | $26.55M | $134.00K | $-265.36M | $-238.66M | $372.22M | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $-194.39M | (m) | (m) | 3 month · $1.13M | 6 month · $0.00 |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | $-191.57M | (m) | (m) | 3 month · $543.00K | 3 month · $0.00 |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $-174.52M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |